New strategies for treating Pseudomonas aeruginosa pulmonary
infection are urgently needed. Adipose tissue-derived mesenchymal stem cells (ASCs) may have a potential therapeutic role in P. aeruginosa-induced pulmonary
infection.
METHODS: ASCs exhibited protective effects against P. aeruginosa pulmonary
infection, evidenced by reduced bacterial burdens, inhibition of alveolar neutrophil accumulation, decreased levels of
myeloperoxidase, macrophage inflammatory protein-2 and total
proteins in broncho-alveolar lavage fluid (BALF), and attenuated severity of
lung injury. ASCs had no effects on BALF and serum levels of
keratinocyte growth factor or Ang-1. ASCs had no effects on the levels of
insulin growth factor 1 (IGF-1) in BALF, but increased
IGF-1 levels in serum. ASCs inhibited the overproduction of
prostaglandin E2 (
PGE2 ) by decreasing the expression of
cyclooxygenase-2 (COX2) and enhancing the expression of
15-PGDH. In addition, the addition of exogenous
PGE2 with ASCs abolished many of the protective effects of ASCs, and administrating
PGE2 alone exacerbated lung
infection. By inhibiting production of
PGE2 , ASCs improved phagocytosis and the bactericidal properties of macrophages. Furthermore suppressing
PGE2 signaling by COX2 inhibition or EP2 inhibition exhibited protective effects against pulmonary
infection as well.
CONCLUSIONS: In a murine model of P. aeruginosa
pneumonia, ASCs exhibited protective effects by inhibiting production of
PGE2 , which subsequently improved phagocytosis and the bactericidal properties of macrophages. ASCs may provide a new strategy for managing pulmonary
infection caused by P. aeruginosa.